Navigation Links
Trial Set to See if Drug Can Prevent Alzheimer's
Date:5/15/2012

TUESDAY, May 15 (HealthDay News) -- Researchers are preparing to test an experimental drug in people genetically primed to develop Alzheimer's disease.

The best-scenario hope is that the drug will lead to a way of preventing the progressive brain-wasting disease, and to a better understanding of its destructive processes, U.S. officials announced Tuesday.

The study volunteers will include some Americans as well as 300 members of an extended Colombian family -- some only 30 years old -- thought to have more relatives with Alzheimer's than any family in the world, The New York Times reported.

None of the study participants will have any signs of dementia at the start of the five-year, $100 million study. Dr. Francis Collins, director of the U.S. National Institutes of Health, said this study is "the first to focus on people who are cognitively normal but at very high risk for Alzheimer's disease," according to the Times.

People with a certain genetic mutation are predestined to develop early-onset Alzheimer's. For this group, dementia typically sets in by about age 50, and signs of thinking and memory problems are evident by age 45.

It's hoped that the study will reveal clues to the development and treatment of Alzheimer's -- the leading cause of dementia -- in other people as well, not just those with what doctors call early-onset Alzheimer's.

The trial is designed to test the widely held theory that Alzheimer's is caused by a buildup in the brain of a protein called beta amyloid. The experimental drug -- crenezumab, which is made by Genentech of South San Francisco -- is designed to attack the formation of beta amyloid plaque.

Currently, there is no cure for Alzheimer's, which affects 5.4 million Americans, or one in eight older adults. And as the baby boom generation ages, those numbers are expected to balloon, creating a major public health crisis in the United States.

Experts on Alzheimer's disease welcomed the announcement of the drug trial.

"This strategy is our best chance of success at Alzheimer's disease," said Dr. Sam Gandy, associate director of the Alzheimer's Disease Research Center at Mount Sinai School of Medicine and director of Mount Sinai's Center for Cognitive Health, in New York City.

"The main challenges are how to identify who is on their way to [Alzheimer's disease], how early we need to begin prior to symptoms, and how long we will have to run the trial before we can see whether the drug delays onset," added Gandy, chairman emeritus of the Alzheimer's Association's National Medical and Scientific Advisory Council.

More information

For more about Alzheimer's disease, visit the Alzheimer's Association.

-- HealthDay staff

SOURCES: Sam Gandy, M.D., Ph.D., Mount Sinai Chair in Alzheimer's Disease Research, and professor of neurology and psychiatry, and director, Mount Sinai Center for Cognitive Health, and associate director, Mount Sinai Alzheimer's Disease Research Center, Mount Sinai School of Medicine, New York City; The New York Times


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Palpitations are predictive of future atrial fibrillation
2. New Weight-Loss Drug Shows Promise in Trial
3. US spends far more for health care than 12 industrialized nations, but quality varies
4. Analysis Finds Clinical Trials Often Small, of Poor Quality
5. URMC clinical trial tests new regimen for hypertension
6. Brain Tumor Vaccine Shows Promise in Early Trial
7. Cancer trial information leaflets not fit for purpose- new study
8. Statin Alternative Looks Promising in Early Trials
9. Study: Low bone density medications may have protective effect on endometrial cancer
10. $4.2 million grant helps plan, launch first Alzheimers prevention trials
11. Cytori breast reconstruction cell therapy trial results published
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... property taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, ... many overseas retirement havens have extremely low property-tax rates, which contributes to the ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:10/2/2017)... announces the European launch of their new low volume, high throughput ... Cambridge, U.K on October 4th. The new ... unprecedented speed and sensitivity while using far less sample volume through ... ... ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
Breaking Medicine Technology: